Compare Ecolab Inc. (ECL) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Organon & Co. Common Stock — how do they compare? Ecolab Inc. trades at $288.75 (market cap $80.08B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Ecolab Inc. is far larger — about 22.1× Organon & Co. Common Stock's market cap, and Ecolab Inc. pays the higher dividend (1.02%). Which is the better fit depends on your goals — on Pluang, investors hold Ecolab Inc. for 91 Days and Organon & Co. Common Stock for 0 Days on average.
| ECL | OGN | |
|---|---|---|
Market Cap | $80.08B | $3.62B |
Volume | 1,150,296 | 2,892,999 |
Sector | Basic Materials | Health |
52-Week High | $308.35 | $13.81 |
52-Week Low | $245.73 | $5.70 |
Typical Hold Time | 91 Days | 0 Days |
Enterprise Value | $88.86B | $11.04B |
Dividend Yield | 1.02% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $287.79, up 1.23% today, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals, including a 12.57% net income margin and 21.85% ROE, with revenue growth from $16.08B in 2025 to a projected $16.8B in 2026. Recent news highlights its dividend consistency and High-Tech segment growth, while institutional buying and insider purchases reflect confidence.
Outlook is positive with a consensus price target of $326.38, implying 13% upside, driven by earnings beats and digital expansion. Risks include elevated P/E of 38.34 and rising debt from the CoolIT acquisition. The stock remains a buy for growth-oriented investors, balancing steady cash flows with execution risks in a competitive market.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
